Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLOCADE Feasibility Study of carvedilol in dialysis patients
ACTRN12609000174280Phase 3Completed
- Sponsor
- The University of Queensland
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and end-stage kidney disease (ESKD) comparing Carvedilol with Placebo (2 arms). Primary endpoints: Failure to tolerate carvedilol during active run-in, Failure to tolerate carvedilol after randomization and 1 more. Started May 2011; status: completed.
02
Drugs
carvedilol
03
Conditions
cardiac morbidityend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ACTRN12609000174280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000174280.